Related Experiment Video

Updated: Jul 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Cellular immunotherapies for prostate cancer

Douglas G McNeel1

  • 1Department of Medicine/Medical Oncology, University of Wisconsin Comprehensive Cancer Center, K4/518 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA. dm3@medicine.wisc.edu

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|February 20, 2007
PubMed

Insights

New cellular immunotherapies show promise for treating advanced prostate cancer, offering potential benefits with fewer side effects than traditional chemotherapy. This review explores these emerging treatments and their clinical implications for oncologists.

Area of Science:

  • Oncology
  • Immunotherapy
  • Prostate Cancer Research

Background:

  • Prostate cancer is a leading cause of cancer death in US men, often due to metastatic disease resistant to androgen deprivation.
  • Current treatments for castration-resistant prostate cancer, including chemotherapy, offer modest survival benefits and significant side effects.
  • Emerging immune-based therapies present a potential alternative with fewer adverse events.

Purpose of the Study:

  • To review two leading cellular immunotherapies for prostate cancer currently in clinical development.
  • To discuss the potential benefits and risks associated with these novel immune-based treatments.
  • To outline challenges for oncologists in adopting these new prostate cancer therapies.

Main Methods:

  • Review of clinical trial data for two cellular immunotherapies.
  • Analysis of potential benefits and risks compared to existing treatments.
  • Discussion of clinical implementation challenges for oncologists.

Main Results:

  • Cellular immunotherapies show promise for clinical benefit in prostate cancer.
  • These therapies may offer a better safety profile compared to chemotherapy.
  • Further research and clinical evaluation are ongoing.

Conclusions:

  • Cellular immunotherapies represent a significant advancement in prostate cancer treatment.
  • Understanding potential benefits and risks is crucial for oncologists.
  • These novel therapies may change the management of advanced prostate cancer.

More Related Videos

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...